These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. da Silva-Júnior FP; Braga-Neto P; Sueli Monte F; de Bruin VM Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788 [TBL] [Abstract][Full Text] [Related]
4. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study. Ziegler M; Castro-Caldas A; Del Signore S; Rascol O Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949 [TBL] [Abstract][Full Text] [Related]
6. Effects of acute tryptophan depletion on cognition, memory and motor performance in Parkinson's disease. Scholtissen B; Verhey FR; Adam JJ; Prickaerts J; Leentjens AF J Neurol Sci; 2006 Oct; 248(1-2):259-65. PubMed ID: 16756999 [TBL] [Abstract][Full Text] [Related]
7. [Effect of brain cortex phospholipids on some enzymatic reactions of cerebral amino acid decarboxylation and possible therapeutic implications (author's transl)]. Mazzoni S; Toffano G; Castellani A Riv Patol Nerv Ment; 1974 Oct; 95(5):637-50. PubMed ID: 4470263 [No Abstract] [Full Text] [Related]
8. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease. Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211 [TBL] [Abstract][Full Text] [Related]
9. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Merello M; Nouzeilles MI; Cammarota A; Leiguarda R Clin Neuropharmacol; 1999; 22(5):273-6. PubMed ID: 10516877 [TBL] [Abstract][Full Text] [Related]
10. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Rabey JM; Prokhorov T; Miniovitz A; Dobronevsky E; Klein C Mov Disord; 2007 Feb; 22(3):313-8. PubMed ID: 17034006 [TBL] [Abstract][Full Text] [Related]
11. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Ondo WG; Tintner R; Voung KD; Lai D; Ringholz G Mov Disord; 2005 Aug; 20(8):958-63. PubMed ID: 15800937 [TBL] [Abstract][Full Text] [Related]
12. Terguride in fluctuating parkinsonian patients: a double-blind study versus placebo. Pacchetti C; Martignoni E; Bruggi P; Godi L; Aufdembrinke B; Miltenburger C; Voet B; Nappi G Mov Disord; 1993 Oct; 8(4):463-5. PubMed ID: 7901760 [TBL] [Abstract][Full Text] [Related]
14. Intravenous flumazenil for Parkinson's disease: a single dose, double blind, placebo controlled, cross-over trial. Ondo WG; Silay YS Mov Disord; 2006 Oct; 21(10):1614-7. PubMed ID: 16830315 [TBL] [Abstract][Full Text] [Related]
15. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Rascol O; Fabre N; Blin O; Poulik J; Sabatini U; Senard JM; Ané M; Montastruc JL; Rascol A Mov Disord; 1994 Jul; 9(4):437-40. PubMed ID: 7969211 [TBL] [Abstract][Full Text] [Related]
16. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Parkinson Study Group Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852 [TBL] [Abstract][Full Text] [Related]
17. Abnormal excitability of premotor-motor connections in de novo Parkinson's disease. Buhmann C; Gorsler A; Bäumer T; Hidding U; Demiralay C; Hinkelmann K; Weiller C; Siebner HR; Münchau A Brain; 2004 Dec; 127(Pt 12):2732-46. PubMed ID: 15509619 [TBL] [Abstract][Full Text] [Related]
18. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575 [TBL] [Abstract][Full Text] [Related]
19. [Slow-release L-dopa vs. standard L-dopa in Parkinson patients in various stages of the disease. Studies of pharmacokinetics and motor effectiveness]. Bergemann N; Baas H; Fischer PA Nervenarzt; 1994 Apr; 65(4):250-7. PubMed ID: 8015632 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease. Tompson D; Oliver-Willwong R Clin Neuropharmacol; 2009; 32(3):140-8. PubMed ID: 18978485 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]